SEC Company Response from Aditxt, Inc. (ADTX) (CIK 0001726711) (ADTX) — Sep 7, 2018
Aditxt, Inc. (ADTX) (CIK 0001726711)
Date: Sept. 7, 2018 · CIK: 0001726711 · Accession: 0001615774-18-009348
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-10825
Letter
Re: ADiTx Therapeutics, Inc. Offering Statement on Form 1-A/A
September 7, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Tonya Aldave
Filed September 4, 2018
File No. 024-10825
Ladies and Gentlemen:
On behalf of ADiTx Therapeutics, Inc. (the “Company”), I hereby request qualification of the above-referenced Offering Statement at 5:00 p.m. Eastern Time on Tuesday, September 11, 2018, or as soon thereafter as is practicable.
Once the Offering Statement is qualified, please orally confirm the event with our counsel, Sheppard Mullin, Richter & Hampton LLP, by calling Richard Friedman at (212) 634-3031.
Sincerely,
ADiTx Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
September 7, 2018
VIA EDGAR
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Ms. Tonya Aldave
Re:
ADiTx Therapeutics, Inc. Offering Statement on Form 1-A/A
Filed September 4, 2018
File No. 024-10825
Ladies and Gentlemen:
On behalf of ADiTx Therapeutics,
Inc. (the “Company”), I hereby request qualification of the above-referenced Offering Statement at 5:00 p.m. Eastern
Time on Tuesday, September 11, 2018, or as soon thereafter as is practicable.
Once the Offering Statement is
qualified, please orally confirm the event with our counsel, Sheppard Mullin, Richter & Hampton LLP, by calling Richard Friedman
at (212) 634-3031.
Sincerely,
ADiTx Therapeutics, Inc.
By: /s/Amro Albanna
Amro Albanna
Chief Executive Officer
ADiTx
Therapeutics, Inc.
11161
Anderson St., Suite 105-10014 Loma Linda, CA 92354
www.aditxt.com